Zydus Cadila has received the final approval from the USFI)A to market Acetazolamide forInjection USP (US RLD —Diamox for Injection), 500 mg per single-dose vial. It will bemanufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

Acetazolamide is a potent carbonic anhydrase inhibitor, effective in the control of fluidsecretion (e.g. some types of glaucoma), treatment of certain convulsive disorders(e. g. epilepsy) and promotion of diuresis in instances of abnormal fluid retention (e.g. cardiacedema).

The group now has 262 approvals and has so far filed over 350 ANDAs since thecommencement of the filing process in FY 2003-04.